User profiles for Barnaby C Reeves
 | Barnaby ReevesUniversity of Bristol Verified email at bristol.ac.uk Cited by 62446 |
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Non-randomised studies of the effects of interventions are critical to many areas of healthcare
evaluation, but their results may be biased. It is therefore important to understand and …
evaluation, but their results may be biased. It is therefore important to understand and …
RoB 2: a revised tool for assessing risk of bias in randomised trials
Assessment of risk of bias is regarded as an essential component of a systematic review on
the effects of an intervention. The most commonly used tool for randomised trials is the …
the effects of an intervention. The most commonly used tool for randomised trials is the …
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
The number of published systematic reviews of studies of healthcare interventions has
increased rapidly and these are used extensively for clinical and policy decisions. Systematic …
increased rapidly and these are used extensively for clinical and policy decisions. Systematic …
Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery
Background— Red blood cell transfusion can both benefit and harm. To inform decisions
about transfusion, we aimed to quantify associations of transfusion with clinical outcomes and …
about transfusion, we aimed to quantify associations of transfusion with clinical outcomes and …
[HTML][HTML] ROBIS: a new tool to assess risk of bias in systematic reviews was developed
…, JPT Higgins, DM Caldwell, BC Reeves… - Journal of clinical …, 2016 - Elsevier
Objective To develop ROBIS, a new tool for assessing the risk of bias in systematic reviews (rather
than in primary studies). Study Design and Setting We used four-stage approach to …
than in primary studies). Study Design and Setting We used four-stage approach to …
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial
PURPOSE: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal
injections to treat neovascular age-related macular degeneration (nAMD). DESIGN: …
injections to treat neovascular age-related macular degeneration (nAMD). DESIGN: …
[HTML][HTML] Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Background Bevacizumab has been suggested to have similar effectiveness to ranibizumab
for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in …
for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in …
[HTML][HTML] Liberal or restrictive transfusion after cardiac surgery
…, EA Stokes, GD Angelini, BC Reeves - … England Journal of …, 2015 - Mass Medical Soc
Background Whether a restrictive threshold for hemoglobin level in red-cell transfusions, as
compared with a liberal threshold, reduces postoperative morbidity and health care costs …
compared with a liberal threshold, reduces postoperative morbidity and health care costs …
Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two …
Background Although no randomised controlled trial has assessed the midterm effects of
coronary-artery bypass surgery on the beating heart, this technique is being used in more and …
coronary-artery bypass surgery on the beating heart, this technique is being used in more and …
Including non‐randomized studies
This chapter has been prepared by the Non-Randomised Studies Methods Group (NRSMG)
of The Cochrane Collaboration (see Box 13.8. a). It is intended to support review authors …
of The Cochrane Collaboration (see Box 13.8. a). It is intended to support review authors …
